Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

Дата публикации: 28-04-2026 12:00:00

Breakthrough Therapy Designation added to Fast Track Designation, recognising potential for substantial improvement over existing treatments

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B	0	14.39	27-03-2026
2	Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B	0	12.98	30-03-2026
3	GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B	0	19.82	07-01-2026
4	GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH	0	6.94	27-04-2026
5	GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch	0	9.8	11-05-2026
6	Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B	0	10.98	26-02-2026
7	Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B	0	7.23	24-08-2026
8	Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)	0	7.95	19-03-2026
9	Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer	0	9.74	24-08-2026
10	Linerixibat accepted for priority review in China for cholestatic pruritus in patients with primary biliary cholangitis	0	8.52	26-02-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.94. Источник: www.gsk.com.